The Integrative Management of Treatment-Resistant Depression: A Comprehensive Review and Perspectives
Open accessThe DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Abstract
Background: Major depressive disorder is a prevalent and disabling illness. Notwithstanding numerous advances in the pharmacological treatment of depression, approximately 70% of patients do not remit after first-line antidepressant treatment. Methods: The MEDLINE/PubMed, EMBASE and ClinicalTrials.gov electronic databases were searched from inception to October 1, 2013, for randomized controlled trials (RCT), relevant open-label trials, meta-analyses and ongoing trials of pharmacological and psychotherapeutic approaches to treatment-resistant depression (TRD). Results: Switching to a different antidepressant is a useful option following nonresponse to a first-line agent. Although widely used in clinical practice, there is limited evidence to support antidepressant combination for TRD. Notwithstanding evidence for lithium or T 3 augmentation to be successful in TRD, most studies were carried out when participants were treated with tricyclic antidepressants (TCA). Of the available strategies to augment the response to new-generation antidepressants, the use of some atypical antipsychotics is best supported by evidence. Several novel therapeutic options are currently discussed. Evidence suggests that cognitive therapy (CT) is an effective strategy for TRD. Conclusions: The success of switching to a different antidepressant following a first-line agent is supported by evidence, but there is limited evidence for effective combination strategies. Lithium and T 3 augmentation of TCA have the strongest evidence base for successful treatment of TRD. The use of augmentation of newer-generation antidepressants with atypical antipsychotics is supported by a growing evidence base. Current evidence supports CT as an effective strategy for TRD. There is a need for additional large-scale RCT of TRD. The development of new antidepressants targeting novel pathways opens a promising perspective for the management of TRD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Less common reactions were 'electric-shock' sensation [9,59,61,62] , visual and auditory hallucination [63] , nocturnal enuresis [64] , pruritus [65] , and emesis [6] .”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [63]
In the citing paper
“For example, anti-correlation, which refers to the selective reciprocal activation and deactivation of various brain regions, is critical for proper cognitive functioning.32”
From Cognitive Impairment in Major Depressive Disorder (2019) · cites this paper as [32]
In the citing paper
“In recent decades, the target clinical endpoints for MDD treatment have evolved from response (i.e. a 50 % reduction in severity of depressive symptoms from baseline) to the objective of clinical remission [49].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [49]
Citations
Cites
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Self-citationTyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Research works printed but not linked: 8
- 10.1176%2fappi.ps.60.11.1439 · doi:10.1176/appi.ps.60.11.1439 · Paper page
- 10.1192%2fbjp.175.1.12 · DOI · Paper page
- 10.1176%2fappi.ajp.163.7.1161 · doi:10.1176/appi.ajp.163.7.1161 · Paper page
- 10.1176%2fappi.ajp.163.9.1531 · DOI
- 10.1176%2fappi.ajp.163.9.1519 · DOI · Paper page
- 10.1159%2f000334112 · DOI
- 10.3109%2f10401230209147396 · doi:10.3109/10401230209147396 · Paper page
- 10.1176%2fappi.ajp.164.5.739 · DOI · Paper page
Cited by
Items 101–129 of 129
Klinisches Management der therapieresistenten Depression
Baune, B. T., Fromme, S. E., Kiebs, M., & Hurlemann, R. (2024) · Der Nervenarzt · doi:10.1007/s00115-024-01647-z · Cited by 1
Virtual sailing exercise to improve major depressive disorder: A pilot clinical trial protocol
Alvarabie, R., Yun, Y., Gaillard, A., Tirosh, O., Sarai, G., Burjawi, E., Meyer, D., & Xiao, J. (2025) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2025.101510 · Cited by 2
“Therefore, current treatment options for MDD are insufficient to adequately address the disease management of the full range of depressive symptoms and disease management [3], presenting a convincing argument for the development of new therapeutic strategies.”
InfluentialSocial cognition and interactive training for first-episode, drug-naïve MDD patients
Li, J., Li, R., Li, D., Ji, S. S., Luo, X., & Zhang, Y. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1566811 · Cited by 2
Hummad, H., Gairola, P., Matakhov, D., Shah, S., Jeyakkodi, H., Rahming, N., Eze, C., Yassa, M. A., Armbrister, U. S., Christie, S., et al. (2026) · Cureus · doi:10.7759/cureus.107728 · Cited by 1
“Previous systematic reviews have examined aspects of the relationship between inflammation and depression outcomes [16,17], but few have quantitatively synthesized the magnitude of association between baseline inflammatory markers and antidepressant nonresponse across diverse study designs and…”
Poulsen, A. S. R. B., Zaer, H., Søgaard, B., Glud, A. N., Sørensen, J. C. H., & Orłowski, D. (2026) · Brain Structure and Function · doi:10.1007/s00429-026-03115-7 · Cited by 1
“Among individuals with MDD who fail initial treatments, 30–50% do not benefit from alternative first-line antidepressants or combination thera - pies and are classified as having treatment-resistant depres - sion (TRD) (Rush et al. 2006, 2020; Carvalho et al. 2014; Dodd et al. 2021).”
Combination Therapies and Switching of Agents in Depression and Bipolar Disorders
Folsche, T., Maier, H. B., Hillemacher, T., & Frieling, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_437 · Cited by 1
Treatment-resistant mood disorders
Passos, I. C., & Quevedo, J. (2015) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/0101-60830000000054 · Cited by 1
Pan, Z. (2018) · TSpace (University of Toronto) · Cited by 1
Lorenzo‐Luaces, L. (2022) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/tzpd2 · Cited by 1
Was tun, wenn die Therapie nicht anspricht?
jn (2015) · CME · doi:10.1007/s11298-015-1414-6
Pasterkiewicz, U. B. (2017) · UWSpace (University of Waterloo) · Cited by 1
Incidence of Atrial Fibrillation in Acute St-Elevation Myocardial Infarction
Ishtiaq, A., Rasool, A., & Khalil, B. (2018) · Journal of Medicine, Physiology and Biophysics · doi:10.7176/jmpb/52-13
Personalized treatment strategies for depression
van Bronswijk, S. C. (2020) · Research Publications (Maastricht University) · doi:10.26481/dis.20201211sb
Gardhouse, K. (2020) · TSpace (University of Toronto)
Combination Therapies and Switching of Agents in Depression and Bipolar Disorders
Folsche, T., Maier, H. B., Hillemacher, T., & Frieling, H. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_437-1 · Cited by 1
Psychotherapeutic interventions
Cosci, F., & Fava, G. A. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780198746638.003.0018
Fava, G. A. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-76050-1.00014-3
Li, H., Tian, M., Wang, C.-L., Zhou, J., Wang, Z.-G., Zhang, W., Qi, X., & Duan, L. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104223
Pharmacological Approaches to Depression and Treatment-Resistant Depression
Fava, M., Baek, J. H., Nierenberg, A. A., Mischoulon, D., Cusin, C., Cassano, P., & Papakostas, G. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11844-9.00051-5
Safe Deprescribing of Antidepressants
(2024) · Wiley eBooks · doi:10.1002/9781394291052.mdg002
Well-Being Therapy for Depression
Romanazzo, S., & Cosci, F. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_14
Case Report: The Role of Tricyclic Antidepressants in Treating Resistant Depression
de Filippis, R., & Foysal, A. A. (2024) · OALib · doi:10.4236/oalib.1112368 · Cited by 1
Pharmacological Approaches to Depression and Treatment-Resistant Depression
Fava, M., Baek, J. H., Nierenberg, A. A., Mischoulon, D., Cusin, C., Cassano, P., & Papakostas, G. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11972-9.00003-x
Ambresin, G., Leuzinger-Bohleber, M., Fischmann, T., Axmacher, N., Hattingen, E., Bansal, R., & Peterson, B. S. (2024) · Figshare · doi:10.6084/m9.figshare.26641096
Moreira, M. T. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Vulnerabilitätsfaktoren depressiver Rezidive und Rückfälle
Teutenberg, L., & Kircher, T. T. J. (2026) · Der Nervenarzt · doi:10.1007/s00115-026-01945-8
McCullough, J. P., & Long, L. R. (2026) · Cognitive Therapy and Research · doi:10.1007/s10608-026-10736-z
Miranda, H. R. R. (2025) · Repositório Institucional da Universidade Autónoma de Lisboa (Universidade Autónoma de Lisboa)
Metadata
- Authors
- Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S.
- Affiliations
- Universidade Federal do Ceará (BR)
- Deakin University (AU)
- University of Ioannina (GR)
- University Health Network (CA)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 83
- Issue
- 2
- Pages
- 70-88
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W1969922688
- Cited by
- 123
- References
- 168
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 12 · 2023: 5 · 2022: 6 · 2021: 11 · 2020: 11 · 2019: 9 · 2018: 12 · 2017: 9 · 2016: 12 · 2015: 15 · 2014: 6
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Deakin Research Online (Deakin University) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- treatment-resistant depression, major depressive disorder, antidepressant switching, antidepressant combination therapy, lithium augmentation, tricyclic antidepressants, atypical antipsychotics, cognitive therapy, newer antidepressants, psychotherapy
- MeSH terms
- Antidepressive Agents, Combined Modality Therapy, Humans, Cognitive Behavioral Therapy, Treatment Outcome, Antidepressive Agents, Second-Generation, Drug Substitution, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.